Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database

Journal of Pharmaceutical Policy and Practice

Francis Kalemeera¹  Assegid T Mengistu¹  Johannes Gaeseb¹ 

[1] Pharmacology & Pharmacy Policy and Practice, School of Pharmacy, Faculty of Health Sciences, University of Namibia, 340 Mandume Ndemufayo, Windhoek, 9000 Namibia

关键词: Tenofovir;    Substitution;    Adverse reactions;    Namibia;    Tubulopathy;    Renal insufficiency;   

DOI  :  10.1186/s40545-015-0034-6

学科分类：药理学

来源: BioMed Central

【 摘 要 】

Objectives

In the management of HIV infection, tenofovir is preferred to its predecessors – zidovudine and stavudine – in the antiretroviral therapy (ART) nucleoside backbone. Tenofovir’s (TDF) preference is based on its safety profile. Nevertheless, TDF causes adverse reactions, some of which warrant its substitution for patients. The rate of TDF-substitution is suggestive of the rate of occurrence of TDF-related adverse reactions. However, the rate of substitution of TDF with another nucleoside reverse transcriptase inhibitor (NRTI) in Namibia was unknown. The objective of this review was to measure the rate of TDF’s substitution for the period of January 1, 2008 to November 30, 2011, and to compare the gender difference in the rates of TDF’s substitution.

【 授权许可】

Unknown